Skip to main content
BioLineRx Ltd. logo

BioLineRx Ltd. — Investor Relations & Filings

Ticker · BLRX ISIN · US09071M2052 LEI · 529900AKIOSC15Y63R18 TA Manufacturing
Open in API
Filings indexed 1,673 across all filing types
Latest filing 2025-01-07 Regulatory Filings
Country IL Israel
Listing TA BLRX

About BioLineRx Ltd.

https://www.biolinerx.com/

BioLineRx Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for oncology and rare diseases. The company leverages its drug development capabilities to advance novel, early-stage therapeutic candidates through the clinical development process toward regulatory approval. Its pipeline consists of treatments, including small molecules, designed to address unmet medical needs and deliver meaningful benefits to patients. BioLineRx also partners with other drug developers to advance their early-stage programs.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings
2025-01-07 English
424B5
Regulatory Filings
2025-01-07 English
BioLineRx Announces $10 Million Registered Direct Offering
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed with the SEC by BioLineRx Ltd. It explicitly announces a registered direct offering of American Depositary Shares (ADSs) and warrants to raise approximately $10 million. This falls under the category of company fundraising and financing activities. While it is a regulatory filing, the specific content regarding the capital raise makes 'CAP' the most accurate classification.
2025-01-06 English
BioLineRx Announces $10 Million Registered Direct Offering
Report Publication Announcement Classification · 98% confidence The document is a short announcement (1853 chars) from BioLineRx, filed with the Israel Securities Authority (ISA) and referencing NASDAQ CM. The title is "BioLineRx Announces $10 Million Registered Direct Offering". Crucially, the text states: "Attached hereto is a report on *BioLineRx Announces $10 Million Registered Direct Offering* *FORM_6-K_1-Jan-2025_isa.pdf*". This structure—a brief announcement stating that a detailed report (in this case, a Form 6-K, which is a general SEC filing for foreign private issuers) is attached or published—fits the definition of a Report Publication Announcement (RPA) according to the 'MENU VS MEAL' rule. It is announcing the release of the offering details rather than being the full offering document itself. Since RPA is a specific category for such announcements, it is preferred over the general fallback RNS.
2025-01-06 English
6-K
Regulatory Filings
2025-01-06 English
Form S-8
Share Issue/Capital Change Classification · 95% confidence The document explicitly states it is a "FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933" filed by BioLineRx Ltd. on December 27, 2024. Form S-8 is used to register securities offered under employee benefit plans. This specific filing relates to registering additional shares under the "Amended and Restated 2003 Share Incentive Plan." This type of filing is not covered by the standard definitions (10-K, ER, IR, etc.). Since it is a specific SEC registration statement that doesn't fit the primary categories, it falls best under the general regulatory/miscellaneous filing category, which is RNS (Regulatory Filings), as it is a formal filing with the SEC that isn't a periodic report or proxy statement.
2024-12-28 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.